

## Notice under Section 708A(5)(e) of the Corporations Act

11 March 2024: Orthocell Limited ASX: OCC, “Orthocell” or “the Company”) advises that it has today issued 500,000 fully paid ordinary shares (**Shares**) following the conversion of 500,000 performance rights and has also issued 100,000 Shares pursuant to agreements under the Company’s Employee Awards Plan.

The Company gives notice under section 708(5)(e) of the Corporations Act 2001 (Cth) (“**Act**”) that:

- (a) the Shares were issued without disclosure to investors under Part 6D.2 of the Act;
- (b) the notice is being given under section 708A(5)(e) of the Act;
- (c) as at the date of this notice the Company has complied with:
  - (i) the provisions of Chapter 2M of the Act, as they apply to the Company; and
  - (ii) sections 674 and 674A of the Act; and
- (d) as at the date of this notice, there is no information that is ‘excluded information’ within the meanings of sections 708(A)(7) and 708A(8) of the Act that is required to be set out in this notice.

**Release authorised by the Board of Orthocell Limited.**

For more information, please contact:

**General & Investor enquiries**

**Paul Anderson**

**Orthocell Limited**

**Managing Director**

P: +61 8 9360 2888

E: paul.anderson@orthocell.com.au

**Media enquiries**

**Haley Chartres**

**HACK Director**

P: +61 423 139 163

E: haley@hck.digital

### About Orthocell Limited

**ACN 118 897 135**

**Registered Office – Building 191 Murdoch University, 90 South Street, Murdoch WA 6150 Australia**

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell’s portfolio of products include CelGro™ platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+™ was the first product approved for dental GBR applications, is cleared for use in US FDA (510k), Australia (ARTG) and Europe (CE Mark) and is distributed globally by BioHorizons Implant Systems Inc. Remplir™, for peripheral nerve reconstruction, recently received approval and reimbursement in Australia and is distributed exclusively by Device Technologies in the Australian market. SmrtGraft™, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company’s other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer, manufacturing scale up and FDA engagement in advance of a randomised controlled study under FDA supervision.

For more information on Orthocell, please visit [www.orthocell.com](http://www.orthocell.com) or follow us on Twitter [@OrthocellLtd](https://twitter.com/OrthocellLtd) and LinkedIn [www.linkedin.com/company/orthocell-ltd](http://www.linkedin.com/company/orthocell-ltd)

